According to VCBeat, FireGen Biomedicals ("FireGen") has completed its Series A + funding round of tens of millions yuan, with participation from Jiangsu Xinlingchuang Capital and Tianjin Kechuang Angel Capital. Proceeds of this round will be used to further accelerate the registration of several nucleic acid detection reagents and devices for rapid diagnosis.
FireGen is a global biomedical company, founded by a team of returned scientists with 30 years' experience in the world's top pharmaceutical companies. The company has built a new generation of R&D platform of nucleic acid reagents and devices for the serious diseases, and developed innovative gene sequencing kits, genetic detectors and chips to promote the rapid diagnosis of genes into the primary medical system.
FireGen has set up a large R&D center and production base in Kunshan, China, and has branches in countries such as the United States, Australia, and cities including Beijing, Tianjin, Nanjing, Suzhou, Wuhan, and other places. In addition, the company has cooperated with more than 30 foreign distributors.
Up to now, FireGen has provided products and services for thousands of hospitals, pharmaceutical companies, scientific research institutes, and gene testing companies all over the world. Its well-known clients include the Chinese Academy of Sciences, Peking Union Medical College Hospital, PLA General Hospital, Fosun Pharma, and so on.
Previously, FireGen has obtained investment from professional medical funds such as CCBI Health Care Growth Fund and Hairong Capital. Song Keqing, founder and chairman of FireGen, said, "the company holds more than 100 authorized intellectual property rights, with innovative technology to reach the international advanced level. We also have a high-specification GMP factory, while meeting the production standards of the CFDA, CE, and FDA. "
About Jiangsu Xinlingchuang Capital
Jiangsu Xinlingchuang Capital is an investment platform for cutting-edge technology firms in the fields of intelligent manufacturing, big health, and new energy in Jiangsu, Zhejiang and Shanghai. It has abundant resources from government, capital and market in the Yangtze River Delta.
About Tianjin Kechuang Angel Capital
Founded in 2006, Tianjin Kechuang Angel Capital is an investment platform under Tianjin Science and Technology Commission. It invests in science and technology projects with technological strength and potential influence of the high-tech industry and provides enterprises with funds, government projects, entrepreneurship guidance, and other services.